Tscan Therapeutics is trading at $0.29, down 10.45%, with no clearly identified catalyst for the October 5, 2026 decline. - No new company announcement surfaced in available news and filings; the latest listed filings were dated October 2. - The market was higher: the S&P 500 rose 0.57% and Nasdaq 0.90%, so broad-market weakness does not explain the decline. The September restructuring and analyst downgrades are earlier context, not a confirmed cause of this session’s move.